Zobrazeno 1 - 10
of 54
pro vyhledávání: '"Alex Hodge"'
Autor:
Daniel Clayton-Chubb, William Kemp, Ammar Majeed, John S. Lubel, Alex Hodge, Stuart K. Roberts
Publikováno v:
Nutrients, Vol 15, Iss 13, p 2908 (2023)
Thank you for your interesting comment [...]
Externí odkaz:
https://doaj.org/article/f917d6eea2614b3cbea4515200da65d1
Autor:
Mihiri Goonetilleke, Nathan Kuk, Jeanne Correia, Alex Hodge, Gregory Moore, Michael P. Gantier, George Yeoh, William Sievert, Rebecca Lim
Publikováno v:
Stem Cell Research & Therapy, Vol 12, Iss 1, Pp 1-13 (2021)
Abstract Background Non-alcoholic fatty liver disease is the most common liver disease globally and in its inflammatory form, non-alcoholic steatohepatitis (NASH), can progress to cirrhosis and hepatocellular carcinoma (HCC). Currently, patient educa
Externí odkaz:
https://doaj.org/article/e6d6b91ca0be446bbc2ca67bfcc4f68e
Autor:
Daniel Clayton-Chubb, William Kemp, Ammar Majeed, John S. Lubel, Alex Hodge, Stuart K. Roberts
Publikováno v:
Nutrients, Vol 15, Iss 3, p 687 (2023)
While non-alcoholic fatty liver disease (NAFLD) is a prevalent and frequent cause of liver-related morbidity and mortality, it is also strongly associated with cardiovascular disease-related morbidity and mortality, likely driven by its associations
Externí odkaz:
https://doaj.org/article/c81cd2323642408d83ece3d8faed979f
Autor:
Zobair M. Younossi, Azza Karrar, Mariaelena Pierobon, Aybike Birerdinc, Maria Stepanova, Dinan Abdelatif, Zahra Younoszai, Thomas Jeffers, Sean Felix, Kianoush Jeiran, Alex Hodge, Weidong Zhou, Fanny Monge, Lakshmi Alaparthi, Vikas Chandhoke, Zachary D. Goodman, Emanuel F. Petricoin
Publikováno v:
BMC Medicine, Vol 16, Iss 1, Pp 1-13 (2018)
Abstract Background Non-alcoholic steatohepatitis (NASH) is among the leading causes of liver disease worldwide. It is increasingly recognized that the phenotype of NASH may involve a number of different pathways, of which each could become important
Externí odkaz:
https://doaj.org/article/7f7defeded5b4a4cbe23233ca72ace90
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Emanuel F. Petricoin, John D. Carpten, Joyce A. O'Shaughnessy, Lance A. Liotta, Brian Leyland-Jones, Massimo Cristofanilli, David W. Craig, Ting Dong, Nicholas Hoke, Bryant Dunetz, Rosa I. Gallagher, Guido Gambara, Julia Wulfkuhle, Linda Vocila, Mohammad Jahanzeb, Donald W. Northfelt, Nicholas J. Robert, Stephen P. Anthony, Sara Byron, Jessica Aldrich, K. Alex Hodge, Shukmei Wong, Corinne Ramos, Mariaelena Pierobon
AKT S473 distribution based on ER, HER2 expression measured by IHC in for primary and metastatic lesions included in the validation set.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f391afae235a8ac682b897d3a84a489
https://doi.org/10.1158/1078-0432.22462946.v1
https://doi.org/10.1158/1078-0432.22462946.v1
Autor:
Emanuel F. Petricoin, John D. Carpten, Joyce A. O'Shaughnessy, Lance A. Liotta, Brian Leyland-Jones, Massimo Cristofanilli, David W. Craig, Ting Dong, Nicholas Hoke, Bryant Dunetz, Rosa I. Gallagher, Guido Gambara, Julia Wulfkuhle, Linda Vocila, Mohammad Jahanzeb, Donald W. Northfelt, Nicholas J. Robert, Stephen P. Anthony, Sara Byron, Jessica Aldrich, K. Alex Hodge, Shukmei Wong, Corinne Ramos, Mariaelena Pierobon
Supplementary material legend
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b1ed9b0ad50ef52c701cade9f9f7a2af
https://doi.org/10.1158/1078-0432.22462958.v1
https://doi.org/10.1158/1078-0432.22462958.v1
Autor:
Emanuel F. Petricoin, John D. Carpten, Joyce A. O'Shaughnessy, Lance A. Liotta, Brian Leyland-Jones, Massimo Cristofanilli, David W. Craig, Ting Dong, Nicholas Hoke, Bryant Dunetz, Rosa I. Gallagher, Guido Gambara, Julia Wulfkuhle, Linda Vocila, Mohammad Jahanzeb, Donald W. Northfelt, Nicholas J. Robert, Stephen P. Anthony, Sara Byron, Jessica Aldrich, K. Alex Hodge, Shukmei Wong, Corinne Ramos, Mariaelena Pierobon
Concordance between PIK3CA, AKT, and PTEN mutation status and AKT (S473) and p70S6 (T389) activation.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::686a053802dd2d2f909f407b4fe898c4
https://doi.org/10.1158/1078-0432.22462961
https://doi.org/10.1158/1078-0432.22462961
Autor:
Emanuel F. Petricoin, John D. Carpten, Joyce A. O'Shaughnessy, Lance A. Liotta, Brian Leyland-Jones, Massimo Cristofanilli, David W. Craig, Ting Dong, Nicholas Hoke, Bryant Dunetz, Rosa I. Gallagher, Guido Gambara, Julia Wulfkuhle, Linda Vocila, Mohammad Jahanzeb, Donald W. Northfelt, Nicholas J. Robert, Stephen P. Anthony, Sara Byron, Jessica Aldrich, K. Alex Hodge, Shukmei Wong, Corinne Ramos, Mariaelena Pierobon
Purpose: Little is known about the molecular signatures associated with specific metastatic sites in breast cancer. Using comprehensive multi-omic molecular profiling, we assessed whether alterations or activation of the PI3K–AKT–mTOR pathway is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d1210473c8d3ef5f7db69708c6deae6
https://doi.org/10.1158/1078-0432.c.6525269.v1
https://doi.org/10.1158/1078-0432.c.6525269.v1
Autor:
Maysa M. Abu-Khalaf, K. Alex Hodge, Christos Hatzis, Elisa Baldelli, Emna El Gazzah, Frances Valdes, William M. Sikov, Monica M. Mita, Neelima Denduluri, Rita Murphy, Daniel Zelterman, Lance Liotta, Bryant Dunetz, Rick Dunetz, Emanuel F. Petricoin, Mariaelena Pierobon
Publikováno v:
npj Precision Oncology. 7
Endocrine therapy (ET) in combination with CDK4/6 inhibition is routinely used as first-line treatment for HR+/HER2− metastatic breast cancer (MBC) patients. However, 30–40% of patients quickly develop disease progression. In this open-label mult